CURE15h
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March ...
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...
TMCnet18h
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...
EE World Online6d
FAQ on three-phase AC power: part 1
This FAQ will look at the advantages and attributes of three-phase AC, also called multiphase or polyphase AC.
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; ...
Applied Clinical Trials Online5d
Phase III DIPPER Trial Shows Camrelizumab Boosts Event-Free Survival in Advanced Nasopharyngeal Carcinoma
Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy ...
Opus Genetics, Inc.: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment ...
USC vs. Mississippi State live updates: JuJu Watkins goes for women's basketball Sweet 16
No. 1 USC and No. 9 Mississippi face each other in the second round of the 2025 women's NCAA Tournament on Monday. Here's ...
Business Wire14d
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The CMO Inducement Grant has an exercise price ... a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and ...